ECONOMIC ANALYSIS OF ETANERCEPT AS CONTINUOUS OR PAUSED THERAPY IN MODERATE TO SEVERE PSORIASIS FROM A PUBLIC PERSPECTIVE IN ARGENTINA

被引：0
|
作者：
Fernandes, R. A. [1 ]
Takemoto, M. L. S. [1 ]
Amaral, L. M. [1 ]
Cruz, R. B. [1 ]
Mould, J. F. [2 ]
机构：
[1] ANOVA Knowledge Translat, Rio De Janeiro, RJ, Brazil
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A252 / A252
页数：1
相关论文
共 50 条
  • [31] Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast
    Bagel, Jerry
    Stolshek, Bradley S.
    Yang, Yue
    Kricorian, Gregory
    Kircik, Leon H.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (04) : 378 - 383
  • [32] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
    Lebwohl, Mark G.
    Kircik, Leon
    Duffin, Kristina Callis
    Pariser, David
    Hooper, Michele
    Wenkert, Deborah
    Thompson, Elizabeth H. Z.
    Yang, Jun
    Kricorian, Greg
    Koo, John
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) : 385 - 392
  • [33] Baseline characteristics of patients with moderate to severe plaque psoriasis: post-hoc analysis of response to etanercept
    Gisondi, Paolo
    Girolomoni, Giampiero
    de Vlam, Kurt
    Al Hammadi, Anwar
    Carneiro, Sueli
    Arenberger, Petr
    Gallo, Gaia
    Jones, Heather
    Hsu, Ming-Ann
    Ferdousi, Tahmina
    Szumski, Annette
    Chhabra, Amit
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S26 - S26
  • [34] Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial
    Thaci, D.
    Galimberti, R.
    Amaya-Guerra, M.
    Rosenbach, T.
    Robertson, D.
    Pedersen, R.
    Yang, S.
    Kuligowski, M.
    Boggs, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (07) : 900 - 906
  • [35] COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
    Feldman, S. R.
    Augustin, M.
    Martin, S.
    Szapary, P.
    Schenkel, B.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [36] ECONOMIC EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
    Fernandes, R. A.
    Takemoto, M. L. S.
    Tolentino, A. C. M.
    Takemoto, M. M. S.
    Santos, P. M. L.
    Mould, J. F.
    VALUE IN HEALTH, 2011, 14 (07) : A309 - A309
  • [37] Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy: reply from author
    Lowe, NJ
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (04) : 832 - 832
  • [38] Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks
    Krishnan, R.
    Cella, D.
    Leonardi, C.
    Papp, K.
    Gottlieb, A. B.
    Dunn, M.
    Chiou, C. F.
    Patel, V.
    Jahreis, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (06) : 1275 - 1277
  • [39] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA
    Obando, C. A.
    Desanvicente-Celis, Z.
    Herrera, J. A.
    Moreira, M.
    De Castro, J.
    VALUE IN HEALTH, 2014, 17 (07) : A607 - A607
  • [40] Effectiveness and safety of continuous versus intermittent etanercept therapy in patients with psoriasis: Analysis of the EASE trial
    Gordon, K
    Kang, SW
    Xia, HA
    Stevens, SR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB216 - AB216
12345